Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/medicine-products/olk-membrane-peeler-1132-1/;msg90356) was not found.

Search medicine products olk membrane peeler 1132 1 ;msg90356 at Google

Search medicine products olk membrane peeler 1132 1 ;msg90356 at Yahoo

Search medicine products olk membrane peeler 1132 1 ;msg90356 at Msn

Google
 
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
Breaking Biology News(10 mins):Lifelong memories linked to stable nerve connections 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 1Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 2Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 3Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 4Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 5Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 6Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 7Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 8Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 9Patients Say Costs Determining Factor in Their Treatment Decisions 48414 1Patients Say Costs Determining Factor in Their Treatment Decisions 48414 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 5
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
Anti-JIP 1 / 2 (SH3) Polyclonal Antibody, Unconjugated, Clone ZMD.177 from Invitrogen
Rabbit Anti-oligophrenin-1 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Mouse Anti-Rat WAVE 1 Monoclonal Antibody, Unconjugated, Clone 1.T.4 from Abcam
Goat Anti-KV beta.1 (Q-13) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products:
Creatine Kinase (CK-NAC)
Alanine Aminotransferase (ALT) GPT
Alkaline Phosphatase (ALP) (DIMENSION)
...ost other EMR,systems require you to,change th...c patient charting,solution designed to fit into...round,five specific criteria to,enhance overal...oPad allows you to see,more patients in the same...
Medicine Products:
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Neurostimulation - A Global Market Perspective ,, http://www.reportlinker.com/p01642
Breaking Biology Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 1Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 2Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 3Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 4Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 1Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 2Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 3